Cooper Companies (NASDAQ:COO) Receives Buy Rating from Stifel Nicolaus

Stifel Nicolaus reaffirmed their buy rating on shares of Cooper Companies (NASDAQ:COO) in a research report released on Thursday morning, Benzinga reports. The brokerage currently has a $115.00 price target on the medical device company’s stock, up from their previous price target of $110.00.

A number of other research firms have also weighed in on COO. Piper Sandler raised their price target on shares of Cooper Companies from $115.00 to $120.00 and gave the company an overweight rating in a report on Thursday. Wells Fargo & Company raised their price target on shares of Cooper Companies from $110.00 to $115.00 and gave the company an overweight rating in a report on Thursday. Jefferies Financial Group raised shares of Cooper Companies from a hold rating to a buy rating and raised their price target for the company from $107.00 to $115.00 in a report on Tuesday, July 16th. Needham & Company LLC reaffirmed a hold rating on shares of Cooper Companies in a report on Thursday. Finally, Robert W. Baird raised their price target on shares of Cooper Companies from $118.00 to $125.00 and gave the company an outperform rating in a report on Thursday. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and an average price target of $113.61.

Cooper Companies Price Performance

Cooper Companies stock opened at $105.73 on Thursday. Cooper Companies has a 52-week low of $75.93 and a 52-week high of $106.95. The firm has a fifty day moving average of $91.53 and a 200-day moving average of $94.22. The firm has a market capitalization of $21.05 billion, a P/E ratio of 62.10, a PEG ratio of 2.56 and a beta of 0.98. The company has a quick ratio of 1.14, a current ratio of 1.99 and a debt-to-equity ratio of 0.33.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings data on Wednesday, August 28th. The medical device company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.91 by $0.05. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $997.30 million. During the same quarter in the prior year, the business earned $0.84 earnings per share. The business’s quarterly revenue was up 7.8% compared to the same quarter last year. As a group, analysts predict that Cooper Companies will post 3.66 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Franklin Resources Inc. lifted its position in shares of Cooper Companies by 1.2% in the 4th quarter. Franklin Resources Inc. now owns 3,401 shares of the medical device company’s stock worth $1,287,000 after buying an additional 41 shares during the last quarter. KLR Investment Advisors LLC lifted its position in shares of Cooper Companies by 4.3% in the 4th quarter. KLR Investment Advisors LLC now owns 1,117 shares of the medical device company’s stock worth $423,000 after buying an additional 46 shares during the last quarter. New York Life Investment Management LLC lifted its position in shares of Cooper Companies by 0.6% in the 4th quarter. New York Life Investment Management LLC now owns 7,783 shares of the medical device company’s stock worth $2,945,000 after buying an additional 49 shares during the last quarter. Quadrant Capital Group LLC lifted its position in shares of Cooper Companies by 10.8% in the 4th quarter. Quadrant Capital Group LLC now owns 613 shares of the medical device company’s stock worth $232,000 after buying an additional 60 shares during the last quarter. Finally, Westpac Banking Corp lifted its position in Cooper Companies by 18.8% in the 4th quarter. Westpac Banking Corp now owns 543 shares of the medical device company’s stock valued at $205,000 after purchasing an additional 86 shares during the last quarter. 24.39% of the stock is currently owned by institutional investors.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.